title: Carboplatin +/- topotecan ophthalmic artery chemosurgery for intraocular retinoblastoma.
abstract: OBJECTIVE
  Carboplatin administered systemically or periocularly can result in dramatic and prompt regression of retinoblastoma. However, both routes are rarely curative alone and have undesirable side effects. We aimed to assess the efficacy and toxicity of carboplatin +/- topotecan delivered by ophthalmic artery chemosurgery whereby chemotherapy is infused into the eye via the ophthalmic artery.
  
  
  METHODS
  This retrospective, IRB-approved study investigated retinoblastoma patients whom received carboplatin +/- topotecan ophthalmic artery chemosurgery. Patient survival, ocular survival, hematologic toxicity, ocular toxicity, second cancer development and electroretinogram response were all evaluated.
  
  
  RESULTS
  57 carboplatin +/- topotecan infusions (of 111 total) were performed in 31 eyes of 24 patients. The remaining infusions were melphalan-containing. All patients were alive and no patient developed a second malignancy at a median follow up of 25 months. The Kaplan-Meier estimate of ocular survival at two years was 89.9% (95% confidence interval [CI], 82.1-97.9%) for all eyes. Grade 3 or 4 neutropenia developed in two patients and one patient developed metastatic disease. By univariate analysis, neither increasing maximum carboplatin/topotecan dose nor cumulative carboplatin/topotecan dose was associated with statistically significant reduction in the electroretinogram responses.
  
  
  CONCLUSIONS
  Carboplatin +/- topotecan infusions are effective for ophthalmic artery chemosurgery in retinoblastoma: they demonstrate low hematologic and ocular toxicity and no statistically significant influence on electroretinogram responses, and used in conjunction with melphalan-containing OAC, demonstrate excellent patient survival and satisfactory ocular survival.
authors.affiliation: Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. francij1@mskcc.org
authors.forename: Jasmine H
authors.initials: JH
authors.lastname: Francis
authors.forename: Y Pierre
authors.initials: YP
authors.lastname: Gobin
authors.forename: Ira J
authors.initials: IJ
authors.lastname: Dunkel
authors.forename: Brian P
authors.initials: BP
authors.lastname: Marr
authors.forename: Scott E
authors.initials: SE
authors.lastname: Brodie
authors.forename: Gowtham
authors.initials: G
authors.lastname: Jonna
authors.forename: David H
authors.initials: DH
authors.lastname: Abramson
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002675:Child, Preschool; D003131:Combined Modality Therapy; D004596:Electroretinography; D005134:Eye Neoplasms / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009880:Ophthalmic Artery / Q000601:surgery*; D012175:Retinoblastoma / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery*; D019772:Topotecan / Q000008:administration & dosage
chemical_list: D019772:Topotecan; D016190:Carboplatin